Rheumnow Podcast

SLGT-2 and GLP-1 in RA: More than Weight Loss ACR2025 Day 1 RECAP

Cellular Biomarkers of Rheumatoid Arthritis Day 2 Recap: ACR Convergence 2025 Highlights

STOP RA Cellular & Serologic Predictors Rheumatoid Arthritis: Inject the Steroids Is Low Disease Activity Low Enough?

Catching PsA before it Starts Day 2 Recap: ACR Convergence 2025 Highlights

PsA and Brain Fog GLP-1 Receptor Agonists in PsA: Mortality and MACE PsA Predictors When the Back Hurts: uncovering BASDAI drivers in PsA The Upper Hand in PsA? Not the Dominant One

Diagnostic Delays in PsA: A Radiographic Perspective Late-Breaking Trials in axSpA and PsA New Approaches to Therapy in PsA

Psoriatic Arthritis Imaging Specialized Biomarkers in PsA PsA: Impact of Sex GLP-1 and SGLT-2: Treatments Too Good to Ignore?

Safety of NSAIDs in Inflammatory Bowel Disease Screen RA ILD Properly Biologics Improve Sexual Function in axSpA Catching PsA before it Starts Multidimensional Pain inventory in Axial SpA RA: Does upfront TNFi save heartache? Novel Insights into Sjogren's Disease New Paradigms in RA Treatment Biomarkers in Still's and Macrophage Activation Syndrome "The Power of Gamma Delta T Cell for Autoimmunity" The Heartbreak of Sarcoidosis

NSAID Addition Helps the Spine but not the Hips Durability and Safety of Bimekizumab Progressive BiTE in SLE 2 Hydroxychloroquine Reduces Autoantibody Levels When the Back Hurts: uncovering BASDAI drivers in PsA The Upper Hand in PsA? Not the Dominant One Airway Disease in GPA Wired for Success: Vagal Nerve Therapy in RA GLP-1 in Knee Osteoarthritis Disparities in Physical Function in SLE

Putting Steroid Tapering into Practice in SLE Tocilizumab Beats Methotrexate in GCA GLP-1 Receptor Agonists in PsA: Mortality and MACE Safety of CAR-T ILD in Patients with Connective Tissue Disease SLGT-2 and GLP-1 in RA: More than Weight Loss PsA Predictors Ianalumab: Breakthrough Therapy in Sjogren's

Off the Shelf: CAR-T Combining CAR-T with CAR-Treg All in One Tapering in SELECT GCA: Steroids are the Problem Diagnostic Delays in PsA: A Radiographic Perspective Late-Breaking Trials in axSpA and PsA New Approaches to Therapy in PsA PRED-SAFE: Chronic Prednisone Use PsA and Brain Fog CAR-T Therapy: Where is it Heading?

Join RheumNow Faculty Drs. David Liew, Antoni Chan, Mrinalini Dey, and Jack Cush as they discuss highlights and key takeaways from the Day 2 Recap on Monday, October 27th, at the 2025 ACR Convergence meeting in Chicago.

A Nose for Vasculitis: ENT Manifestations in ANCA-Associated Disease Tofacitinib in AxSpA in Developing Countries Specialized Biomarkers in PsA B Cell Depletion: Check the Lymph Node GLP-1 and SGLT-2: Treatments Too Good to Ignore? Nerandomilast for ILD PsA: Impact of Sex Cellular Biomarkers of Rheumatoid Arthritis Using AI and LLMs in Qualitative Data Belimumab Before or After Immunosuppressant Do Patients with Rheumatic Diseases 'Weather' the Storm? AI in Fellow Recruitment: A New Dawn in Medical Education?

AI Scribes Found their Favorite Doctors Hospitalization in Stills: Is it "Still" an Infection? Upadacitinib is a Double Edged Vascular Sword in GCA Rheumatoid Arthritis: Inject the Steroids Catching AxSpA Early: Closing the Diagnostic Gap Is Low Disease Activity Low Enough? Early Peripheral SpA: Is it okay to stop treatment sometimes? Difficult to Manage axSpA

STOP RA Cellular & Serologic Predictors Is AI Smarter than a Doctor? Lung Disease in ANCA-associated Vasculitis Older Adults Underrepresented in RCTs Next Generation T-Cell Engager: The Future Lupus in Focus: 2025 ACR Treatment Guidelines for SLE Psoriatic Arthritis Imaging

Big takeaways, standout moments, and what set the tone for this year’s conference. We break down the key insights, early trends, and conversations shaping Day 1.

Dr. Jack Cush reviews the news and info reports the day before ACR 2025.

DERM on RheumNow PODCAST (October 2025) Skin important Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTES 1. Skin Biopsies to Predict Scleroderma Outcomes? 2. Fibromyalgia in PsO & PsA is linked to greater treatment complexity and shorter biologic therapy survival. Retro matched 1:4 cohort study 61K PsO& 244K controls. FM prevalence 3.3% (OR 1.45). In PsA w/ FM, req more biologics w/ decr biologic survival (6 vs 10yrs) w/ incr switching (HR 1.82) https://buff.ly/TCc6Kc8 3. Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis https://rheumnow.com/news/guselkumab-fda-approved-pediatric-psoriasis-and-psoriatic-arthritis 4. Sonelokimab (SLK) is a nanobody that inhibits IL-17 A&F. Phase 2 ARGO trial 207 active PsA pts Rx w/ SLK 120-mg or 60-mg q4wks or PBO or adalimumab. ACR50 at wk 12 was 60-mg WI=46%; 120-mg WI=46%; PBO 20%. PASI90: 60mg 77% vs 120mg 59% vs PBO 15% https://t.co/ra0NqvUEru https://t.co/FXT6kkXUzH 5. Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition time (~13 yrs) from PsO-to-PsA. Factors assoc w/ prolonged interval included Depression, fatigue, scalp PsO(OR 7), nail PsO (3.2), +Fhx & enthesitis ever (OR 2) https://t.co/wqtSbeQ2vz 6. Mediterranean Diet Efficacy in Psoriasis 7. Gender Complexities in Psoriatic Arthritis Treatment Outcomes

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.

Our final webinar in this month's Rheum to Breathe: ILD campaign brings together ILD experts to discuss best practices in diagnosis, screening, and monitoring, covering: tools, labs, and imaging; timing and frequency of screening; ILD screening in RA; and, referral strategies. Panelists: Shane Shapera, MD Elana Bernstein, MD Bryant England, MD Moderator: Jack Cush, MD

Experts Dr. Jeffrey Curtis and Dr. Kevin Winthrop discuss best practices for shared decision-making, how to talk with patients about the risks of poorly controlled RA, and ways to use a new tool for visualizing the long-term safety of a JAKi.

QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign ILD QD Clinic #4 ILD QD Clinics - Worsening Breathlessness in SSc ILD: The Pressure Is On ILD QD clinics on ILD #1 - Be Careful What you Look For

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 4: Rheum + Pulm Collaborations in ILD including The Rheumatologist and Pulmonologist: Different approaches to the same patient (Dr. Paul Dellaripa and Dr Rachel Putman).

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 3: ILD Assessment and Management including: Biomarkers in ILD (Dr. Elena Joerns), How to Assess ILD in Patients (Dr. Janet Pope) and Management of SSc ILD (Dr. Alicia Hinze)

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 2: ILD Treatment including: RA-ILD Treatment Update (Dr. Bryant England), Do DMARDS Affect CTD-ILD Outcomes? (Dr. Elizabeth Volkmann), Non-pharmacologic Treatment of ILD (Dr. Jon Giles) and Transplantation: A real option! (Dr. John Joerns)

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 1: ILD Guidelines including: ACR/CHEST Guidelines for SSc ILD (Dr. Sindhu Johnson), ERS/EULAR Clinical Practice Guidelines (Dr. Anna-Maria Hoffman-Vold) and ILD Guideline Caveats and Concerns (Dr. Jeffrey Sparks).

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and whats best for knee OA.

QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign ILD QD Clinic #3 ILD QD Clinic: Application of the ACR CHEST Guidelines to Two Cases ILD QD Clinic: Progressive RA-ILD Management ILD QD Clinic: Beyond the Numbers in Newly Diagnosed ILD

In this journal club, we will discuss two pivotal studies in ILD, the FIBRONEER study and the RECITAL study: Nerandomilast in Patients with Progressive Pulmonary Fibrosis, Maher, T.M. et al. NEJM. 2025 May 19. doi: 10.1056 Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial, Maher T.M., et al. Lancet 2023 Jan;11(1). doi: 10.1016 Panelists: Toby Maher, MD Shervin Assassi, MD Jack Cush, Moderator

Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more. Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTES: 1. SMILE Study: A randomized, placebo-controlled trial of hydroxychloroquine in incomplete lupus https://t.co/NnrA8ohiGX 2. Equal Safety of JAK Inhibitors and TNF Inhibitors in H2H IMID trials JAMA systematic review. https://t.co/HI1KBKZiXR 3. SMART study - Single vs. Split Dose Methotrexate https://t.co/lizsrtVHwf 4. Vegan diets don’t work in RA - Metanalysis of 7 studies https://t.co/jeh6gN5Byg 5. No association between IL-17 inhibitors & MACEs (vs TNFi Rx) https://t.co/fJuPFYKnSr https://t.co/Vscnsq0DTA 6. Successful Phase 3 UP-AA Trial evaluating Upadacitinib in Alopecia Areata (AA) https://t.co/8p1FvJx0s0 7. Anifrolumab effective & safe in refractory Cutaneous LE - OL Study in 15 CLE https://t.co/umEYz0XDyt 8. "Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has." - Margaret Mead https://t.co/OFGN223bPa

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs wont do & an FDA Pink Slip.

This deep dive into controversies in interstitial lung disease explored complex topics including IPAF, methotrexate, systemic autoimmune rheumatic disease vs. connective tissue disease distinctions, and the evolving role of anti-fibrotic therapy. Panelists: Jeffrey Sparks, MD, Janet Pope, MD, Elena Joerns, MD Jack Cush, MD - Moderator

Dr. Peter Nash, Australia, reports highlights from a range of sessions presented at the APLAR 2025 Congress in Fukuoka, Japan. Hot Topics in AxSpA Precision Medicine in PsA PSA Therapeutic Update CAR T Therapy with Immunomediated Diseases Imaging Use of Micro CT Low Radiation for PsA

"QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign. Here are the individual video titles and links: ILD QD Clinic: Stick or twist (when not to change treatment) https://youtu.be/sdGPsvcfyzQ ILD QD Clinic: Interstitial Lung Disease with Positive SSA and Rash https://youtu.be/1H10_VR8t_0 ILD QD Clinic Video: RA and Bronchiectasis https://youtu.be/-StSi3v8ew8

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are their benefits to Diet/vegan diets? Whats the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month.

Rheum to Breathe “ILD and Autoimmune Disease”: RA ILD Complications (Scott Matson): https://youtu.be/xTLvKLwlF-E ILD and Mortality (Bryant England): https://youtu.be/Ew9OW2o43Bg ILD in Sjorgen's (Nancy Cateron):https://youtu.be/BLVF2qvoR7E Truth of Fake: Idiopathic Interstitial Pneumonia with Autoimmune Features (Janet Pope): https://youtu.be/4Jk7nVeLIR8

This webinar will review the ACR and EULAR guidelines on interstitial lung disease, with a focus on ‘where are we now and where are we going?’ in regards to treatment strategies and emerging therapies in ILD care. Panelists: Sindhu Johnson, MD Shane Shapera, MD Scott Matson, MD Jack Cush, MD - Moderator https://youtube.com/live/Viexwyv0sxs?feature=share

"QD clinics on ILD #1 - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign

Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogrens and alot of ILD.

Join panelists as they discuss rheumatologist impressions, knowledge and practices over the last 20 years when treating rheumatoid arthritis. Experts will unpack the results of a nationwide, three-part survey — covering treatment milestones, changing practices, and what the future holds for RA therapy. Don't miss this opportunity to hear what your peers are saying — and where the field is headed. Panelists: Katherine Liao, MD, MPH Stanley B. Cohen, MD Jeff Curtis, MD, MS, MPH Jack Cush, MD - moderator Sponsored by: Bristol Myers Squibb

Dr. Jack Cush reviews the news and journal reports from RheumNow.com. This week news on vaccines, safety of acetaminophen and more.

Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more. Features Dr. Jack Cush, Editor at RheumNow.com.

Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, etc.

Dr. Jack Cush reviews the news, journal reports and press clippings from the past week on RheumNow. Positive results in a Sjogrens trial, to PT or not to PT, and aphorisms to live by.

Dr. Jack Cush reviews the news, reports, pipeline and drug repurposing on this weeks podcast.

Rheumatologists Dr Anca Askanase and Dr Cristina Arriens discuss their clinical perspectives on how to target and achieve DORIS remission in clinical practice. Sponsored by AstraZeneca Medical Affairs

Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.

Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com